Trial Profile
An Open-Label Phase 1/2 Study of VELCADE (Bortezomib) for Injection in Subjects With Light-Chain (AL)-Amyloidosis.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Millennium
- 10 Jun 2010 New trial record
- 05 Jun 2010 Results were presented at ASCO 2010, according to a Millennium media release.